The role of ferroptosis in metabolic diseases

Xie, Ling; Fang, Bin; Zhang, Chun

doi:10.1016/j.bbamcr.2023.119480

Cited by 11 publications

(2 citation statements)

References 186 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These molecules inhibit the expression of Solute Carrier Family 7 Member 11 (SLC7A11) and Solute Carrier Family 3 Member 2 (SLC3A2), two subunits of the xc system, and further direct the target (tumor) cell toward ferroptosis. The study carried out by the scholars thus provides insight into how ferroptosis could be induced within the body as a defense tool against the processes of carcinogenesis [2,5,6] Ferroptosis may be closely linked to the pathogenesis of various conditions including aging, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and autoimmune diseases [7][8][9][10]. For example, in Parkinson's disease, iron accumulation in dopaminergic neurons can lead to ferroptosis and neuronal death.…”

Section: Ferroptosis: An Overviewmentioning

confidence: 99%

Ferroptosis: Emerging Role in Diseases and Potential Implication of Bioactive Compounds

Patanè,

Putaggio,

Tellone

et al. 2023

IJMS

View full text Add to dashboard Cite

Ferroptosis is a form of cell death that is distinguished from other types of death for its peculiar characteristics of death regulated by iron accumulation, increase in ROS, and lipid peroxidation. In the past few years, experimental evidence has correlated ferroptosis with various pathological processes including neurodegenerative and cardiovascular diseases. Ferroptosis also is involved in several types of cancer because it has been shown to induce tumor cell death. In particular, the pharmacological induction of ferroptosis, contributing to the inhibition of the proliferative process, provides new ideas for the pharmacological treatment of cancer. Emerging evidence suggests that certain mechanisms including the Xc− system, GPx4, and iron chelators play a key role in the regulation of ferroptosis and can be used to block the progression of many diseases. This review summarizes current knowledge on the mechanism of ferroptosis and the latest advances in its multiple regulatory pathways, underlining ferroptosis’ involvement in the diseases. Finally, we focused on several types of ferroptosis inducers and inhibitors, evaluating their impact on the cell death principal targets to provide new perspectives in the treatment of the diseases and a potential pharmacological development of new clinical therapies.

show abstract

Section: Ferroptosis: An Overviewmentioning

confidence: 99%

Ferroptosis: Emerging Role in Diseases and Potential Implication of Bioactive Compounds

Patanè,

Putaggio,

Tellone

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition, another possible mechanism of ferritin secretion involves leakage from damaged cells 10 , 11 . Ferroptosis is a recently discovered iron-dependent form of cell death with distinct cellular morphology and biological mechanisms 12 . Therefore, the disruption of iron metabolism induced by ferroptosis may explain the strong association between serum ferritin (SF) and markers of hepatocellular damage.…”

Section: Introductionmentioning

confidence: 99%

Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus

Wang,

He,

Wang

et al. 2024

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY OBJECTIVE: The aim of this study was to assess the role of elevated serum ferritin levels in the onset, pathological progression and prognosis of nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease has been rapidly increasing worldwide. Despite extensive research on the pathogenesis of nonalcoholic fatty liver disease, a lack of sufficient clinical research on the relationship between nonalcoholic fatty liver disease and serum ferritin levels remains. METHODS: We analysed 968 patients with type 2 diabetes mellitus who underwent liver ultrasound examination and had their serum ferritin levels measured. The presence of nonalcoholic fatty liver disease and advanced liver fibrosis was determined through abdominal ultrasound examination and the nonalcoholic fatty liver disease fibrosis score. RESULTS: Compared to that in the non-nonalcoholic fatty liver disease group, the presence of hyperferritinemia was significantly more common in the nonalcoholic fatty liver disease group (83.3 vs. 56.3%, p=0.005). When patients with nonalcoholic fatty liver disease were stratified by the nonalcoholic fatty liver disease fibrosis score, those with advanced liver fibrosis exhibited a higher prevalence of hyperferritinemia (56.3, 78.9, and 88.9% for none, simple steatosis, and advanced fibrosis, respectively; p for trend=0.002). In multivariate logistic regression, liver fibrosis was independently associated with hyperferritinemia (odds ratio [OR] 1.45; 95% confidence interval [CI] 1.18–2.02; p=0.014), and this association remained significant in male patients after adjusting for other risk factors (OR 2.66; 95% CI 1.43–5.48; p=0.026). CONCLUSION: Identifying nonalcoholic fatty liver disease patients at a risk of developing nonalcoholic steatohepatitis and advanced fibrosis is crucial for implementing timely interventions and improving patient outcomes. This study highlights the potential utility of serum ferritin levels as a serum biomarker for identifying nonalcoholic steatohepatitis patients and those at a risk of late-stage fibrosis, particularly in male patients with nonalcoholic fatty liver disease.

show abstract